-
2022-501901-10-00
6
2023-02-06
Chronic Hepatitis D Infection
-
2023-503928-10-00
4
2023-02-01
Prodromal and Early Manifest Huntington’s Disease
-
2023-504832-16-00
4
2023-01-24
DIFFUSE LARGE B CELL LYMPHOMA
-
2024-510837-16-00
4
2022-12-13
locally-advanced and unresectable or metastatic NSCLC with KRAS G12C
-
2023-508701-24-00
5
2022-11-21
Locoregional Hepatocellular Carcinoma (HCC)
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-515637-14-00
5
2022-11-08
Cystic Fibrosis
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2023-503467-41-00
5
2022-10-12
Relapsed or Refractory Multiple Myeloma
-
2024-512368-79-00
4
2022-10-10
Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
-
2024-517239-33-00
5
2022-10-06
Ear, nose and throat diseases
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-505302-42-00
4
2022-09-05
BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2023-510387-13-00
4
2022-05-18
advanced ALK-positive non-small cell lung cancer
-
2024-518244-20-01
4
2022-04-25
Urothelial Carcinoma
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2024-512745-16-00
5
2022-04-13
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2024-515037-15-00
4
2022-03-02
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI
-
2023-506867-33-01
4
2022-01-25
Chronic Hepatitis B
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma